Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications ...

This recent study introduces a non–insulin-specific version of the Diabetes Eating Problem Survey–Revised tool that screens ...

Women using weight-loss injections like Ozempic and Mounjaro are being warned to use contraception, as surprise pregnancies ...

The widespread adoption of GLP-1 (glucagon-like peptide-1) receptor agonist medications, such as Ozempic and Wegovy, is ...

To help you keep the level steady and healthy, your body makes a hormone called glucagon while you sleep and after you eat. It's made in your pancreas, a small organ above your liver, and it can ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Far from eliminating the need for weight-loss procedures, glucagon-like peptide-1 receptor agonists could drive more people to seek them out. At least that’s what Fractyl Health Inc. and Bariendo Inc.

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

I know we wanna cheat the system as Americans, we do,” the 53-year-old tells Page Six in an exclusive interview.

Exenatide is a glucagon-like peptide-1 agonist indicated as an adjunct to diet and exercise to improve glycemic control in ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...